Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors.


Journal

Chemical & pharmaceutical bulletin
ISSN: 1347-5223
Titre abrégé: Chem Pharm Bull (Tokyo)
Pays: Japan
ID NLM: 0377775

Informations de publication

Date de publication:
2020
Historique:
entrez: 3 4 2020
pubmed: 3 4 2020
medline: 19 12 2020
Statut: ppublish

Résumé

Respiratory syncytial virus (RSV) is one of the most common causes of lower respiratory tract infections and a significant pathogen for both adults and children. Although two drugs have been approved for the treatment of RSV infections, the low therapeutic index of these drugs have led pharmaceutical companies to develop safe and effective small-molecule anti-RSV drugs. The pyrazolo[1,5-a]pyrimidine series of compounds containing a piperidine ring at the 2-position of the pyrazolo[1,5-a]pyrimidine scaffold are known as candidate RSV fusion (F) protein inhibitor drugs, such as presatovir and P3. The piperidine ring has been revealed to facilitate the formation of an appropriate dihedral angle between the pyrazolo[1,5-a]pyrimidine scaffold and the plane of the amide bond for exertion of anti-RSV activity. A molecular-dynamic study on newly designed compounds with an acyclic chain instead of the piperidine ring proposed and demonstrated a new series of pyrazolo[1,5-a]pyrimidine derivatives, such as 9c with a 1-methyaminopropyl moiety, showing similar dihedral angle distributions to those in presatovir. Compound 9c exhibited potent anti-RSV activity with an EC

Identifiants

pubmed: 32238652
doi: 10.1248/cpb.c19-00895
doi:

Substances chimiques

Antiviral Agents 0
Pyrazoles 0
Pyrimidines 0
pyrazolo(1,5-a)pyrimidine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

345-362

Auteurs

Toru Yamaguchi-Sasaki (T)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.

Yunoshin Tamura (Y)

Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd.

Yuya Ogata (Y)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.

Takanori Kawaguchi (T)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.

Jun Kurosaka (J)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.

Yutaka Sugaya (Y)

Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd.

Kanako Iwakiri (K)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.

Tsuyoshi Busujima (T)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.

Ryo Takahashi (R)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.

Naoko Ueda-Yonemoto (N)

Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd.

Eiji Tanigawa (E)

Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd.

Tomoko Abe-Kumasaka (T)

Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd.

Hiroyuki Sugiyama (H)

Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd.

Kosuke Kanuma (K)

Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH